This is a prospective, multi-center, randomized pilot study to document the effects of adventitial delivery of dexamethasone after atherectomy-based revascularizations of lesions below the knee in symptomatic patients with critical limb ischemia (CLI).
This is a prospective, multi-center, randomized pilot study to document the effects of adventitial delivery of dexamethasone after atherectomy-based revascularizations of lesions below the knee in symptomatic patients with critical limb ischemia (CLI). Up to 120 patients (60 treatment and 60 control), including up to 20 Rutherford 6 patients (10 treatment and 10 control) at up to 30 sites in the United States and Europe. This study will assess the safety and effectiveness of Bullfrog Micro-Infusion Device adventitial deposition of dexamethasone in reducing inflammation and restenosis in patients with clinical evidence of chronic critical limb ischemia with an angiographically significant lesion in the infrapopliteal crural vessels.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
120
Following atherecomy-based revascularization, Investigators will be unblinded to assignment and will treat only patients assigned to the treatment arm with the Bullfrog delivery of dexamethasone.
Arkansas Heart Hospital
Little Rock, Arkansas, United States
Denver Veterans Administration Hospital
Denver, Colorado, United States
Mid-Michigan Heart & Vascular
Saginaw, Michigan, United States
Freedom from MALE
Freedom from major adverse limb event (MALE) within 6 months.
Time frame: Up to 6 Months following the procedure
Freedom from CD-TLR
Freedom from clinically driven target lesion revascularization (CD-TLR) within 6 months.
Time frame: Up to 6 Months following the procedure
Composite clinical safety by freedom from adverse events including death, MALE, major unplanned amputation, or CD-TLR.
Freedom from composite of death within 30 days from the index procedure, MALE, major unplanned amputation or CD-TLR within 6 months.
Time frame: Up to 6 Months following the procedure
TVAL% change from post-procedure
Transverse-view vessel area loss percentage (TVAL%) of the target lesion at 6 months by quantitative vascular angiography (QVA) or prior to any CD-TLR of the target lesion before 6 months
Time frame: 6 Months following the procedure
Composite clinical safety by freedom from adverse events including death, unplanned amputation, CD-TLR, SAE or MALE.
Freedom from composite of death, unplanned amputation and CD-TLR, serious adverse events (SAE) and MALE.
Time frame: Up to 12 months following the procedure
Event-free survival
Proportion of patients reaching 12-month endpoint without a composite clinical safety event.
Time frame: 12 months following the procedure
QVA change from post-procedure
Improvement in % diameter stenosis (%DSS) of the target lesion (TL) and the maximum late lumen loss for the lesion (LLL) will be assessed by quantitative vascular angiography (QVA).
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Hattiesburg Clinic
Hattiesburg, Mississippi, United States
St.Louis University Hospital
St Louis, Missouri, United States
Holy Name Medical Center
Teaneck, New Jersey, United States
UNC Health Care - Rex Hospital
Raleigh, North Carolina, United States
Sanford Research
Sioux Falls, South Dakota, United States
Tennova - Turkey Creek Medical Center
Knoxville, Tennessee, United States
Mission Research Institute (New Braunfels Cardiology - GRMC)
New Braunfels, Texas, United States
Time frame: 6 months following the procedure
IVUS change from post-procedure
Improvement in intravascular ultrasound (IVUS) result with in the TL (subgroup analysis).
Time frame: 6 months following the procedure
Amputation-free survival
Percentage of patients reaching the endpoints without major or minor amputation.
Time frame: 30 days, 6 and 12 months following the procedure
Major and minor amputations and amputation level
Percentage of patients requiring amputation (major: above ankle, minor: below ankle), categorized by level on the foot, ankle, or leg.
Time frame: 30 days, 6 and 12 months following the procedure
Change in foot wounds versus baseline
The number and total size of foot wounds, reduction in number and size of baseline wounds, and occurrence of new wounds (number and size) will be measured against baseline.
Time frame: 30 days, 6 and 12 Months following the procedure
Resolved CLI death
The rate of deaths in patients who had a resolution of their critical limb ischemia (CLI).
Time frame: 30 days, 6 and 12 months following the procedure
CD-TLR
Time frame: 30 days, 6 and 12 months following the procedure
Primary sustained clinical improvement versus baseline
Sustained upward shift of at least 1 category on Rutherford classification as compared to baseline without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.
Time frame: 30 days, 6 and 12 months following the procedure
Secondary sustained clinical improvement versus baseline
Sustained upward shift of at least 1 category on Rutherford classification as compared to baseline including the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.
Time frame: 30 days, 6 and 12 months following the procedure
SVS WIfI score versus baseline
Time frame: 30 days, 6 and 12 months following the procedure
EQ5D versus baseline
Time frame: 30 days, 6 and 12 months following the procedure
Walking capacity assessment versus baseline
Time frame: 30 days, 6 and 12 months following the procedure
SAE/MALE assessment
Time frame: 30 days, 6 and 12 months following the procedure
Inflammatory biomarker changes from baseline
Time frame: 24 hours and 30 days
Healthcare economic analysis
An analysis of the economics associated with the care of patients, including number of hospital days throughout the study, return visits and hospitalizations, time from index procedure to required revascularization and number of index-lesion-related readmissions.
Time frame: From baseline to 24 months
Infustion technical success
The grade of distribution (A-F) around infusion sites will be used as a qualitative measure of technical success of adventitial delivery of the drug.
Time frame: Intra-procedural
Revascularization success
Establishment of antegrade flow with residual stenosis \<30% by angiogram.
Time frame: Intra-procedural